Supernus Pharma (SUPN) Tops Q4 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Supernus Announces Record Full Year 2018 Financial Results
February 26, 2019 4:56 PM ESTFourth quarter 2018 total revenue of $115.9 million, a 31% increase over 2017, and fourth quarter 2018 net product sales of $113.5 million, a 32% increase over 2017.Fourth quarter 2018 operating earnings of $39.9 million, a 16% increase over 2017.Full year 2018 total revenue of $408.9 million, a 35% increase over 2017. Full year 2018 net product sales of $399.9 million, a 36% increase over 2017.Full year 2018 operating earnings of $144.4 million, a 45% increase over 2017.Positive results from three Phase III studies for SPN-812 in ADHD announced in December 2018.Oxtellar XR® launched in January 2019 with expanded indication to include monotherapy for partial seizures.
ROCKVILLE, Md., Feb. 26, 2019 (GLOBE NEWSWIRE) --... More
